{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:57:13Z","timestamp":1777114633649,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"DOI":"10.7759\/cureus.96564","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:53:13Z","timestamp":1762869193000},"source":"Crossref","is-referenced-by-count":1,"title":["Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity"],"prefix":"10.7759","author":[{"given":"Bethany","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Farley-Hills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wah","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjaak","family":"Pouwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Whiteley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Al-Ardah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Beamish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Hammoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca V","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhaib","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Obesity Federation. (2022). Accessed. October 20, 2025: https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2022."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Di Angelantonio E","year":"2016","unstructured":"Di Angelantonio E, Bhupathiraju ShN, Wormser D, et al.. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016, 388:776-86. 10.1016\/S0140-6736(16)30175-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley TM","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al.. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021, 143:e984-e1010. 10.1161\/CIR.0000000000000973","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23086","article-title":"Describing the weight-reduced state: physiology, behavior, and interventions","volume":"29 Suppl 1","author":"Aronne LJ","year":"2021","unstructured":"Aronne LJ, Hall KD, M Jakicic J, Leibel RL, Lowe MR, Rosenbaum M, Klein S. Describing the weight-reduced state: physiology, behavior, and interventions. Obesity (Silver Spring). 2021, 29 Suppl 1:S9-S24. 10.1002\/oby.23086","journal-title":"Obesity (Silver Spring)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian CM","year":"2015","unstructured":"Apovian CM, Aronne LJ, Bessesen DH, et al.. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015, 100:342-62. 10.1210\/jc.2014-3415","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms RJ","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1?. Trends Endocrinol Metab. 2020, 31:410-21. 10.1016\/j.tem.2020.02.006","journal-title":"Trends Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun T","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, et al.. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018, 18:3-14. 10.1016\/j.molmet.2018.09.009","journal-title":"Mol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar N","year":"2021","unstructured":"Sattar N, Lee MM, Kristensen SL, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021, 9:653-62. 10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241291512","article-title":"Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system","volume":"19","author":"Shah VN","year":"2025","unstructured":"Shah VN, Peters AL, Umpierrez GE, et al.. Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system. J Diabetes Sci Technol. 2025, 19:191-216. 10.1177\/19322968241291512","journal-title":"J Diabetes Sci Technol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He L","year":"2022","unstructured":"He L, Wang J, Ping F, et al.. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022, 182:513-9. 10.1001\/jamainternmed.2022.0338","journal-title":"JAMA Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.033","article-title":"Epidemiology, pathophysiology, and treatment of diverticulitis","volume":"156","author":"Strate LL","year":"2019","unstructured":"Strate LL, Morris AM. Epidemiology, pathophysiology, and treatment of diverticulitis. Gastroenterology. 2019, 156:1282-1298.e1. 10.1053\/j.gastro.2018.12.033","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1548346","article-title":"Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis","volume":"16","author":"Mostafa ME","year":"2025","unstructured":"Mostafa ME, Alrasheed T. Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025, 16:1548346. 10.3389\/fendo.2025.1548346","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.057","article-title":"Metabolism and metabolic disorders and the microbiome: the intestinal microbiota associated with obesity, lipid metabolism, and metabolic health-pathophysiology and therapeutic strategies","volume":"160","author":"Aron-Wisnewsky J","year":"2021","unstructured":"Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Cl\u00e9ment K. Metabolism and metabolic disorders and the microbiome: the intestinal microbiota associated with obesity, lipid metabolism, and metabolic health-pathophysiology and therapeutic strategies. Gastroenterology. 2021, 160:573-99. 10.1053\/j.gastro.2020.10.057","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02032-23","article-title":"Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases","volume":"15","author":"Zeng Y","year":"2024","unstructured":"Zeng Y, Wu Y, Zhang Q, Xiao X. Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. mBio. 2024, 15:e0203223. 10.1128\/mbio.02032-23","journal-title":"mBio"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199603000-00006","article-title":"Pyogenic liver abscess. Changes in etiology, management, and outcome","volume":"75","author":"Seeto RK","year":"1996","unstructured":"Seeto RK, Rockey DC. Pyogenic liver abscess. Changes in etiology, management, and outcome. Medicine (Baltimore). 1996, 75:99-113. 10.1097\/00005792-199603000-00006","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433389-diverticular-stricture-and-hepatic-abscess-formation-during-tirzepatide-therapy-for-obesity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:53:18Z","timestamp":1762869198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433389-diverticular-stricture-and-hepatic-abscess-formation-during-tirzepatide-therapy-for-obesity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.96564","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}